<DOC>
	<DOCNO>NCT00729404</DOCNO>
	<brief_summary>Investigation two transdermal hormone patch formulation contraception regard inhibition ovulation period 3 treatment cycle healthy young female volunteer</brief_summary>
	<brief_title>Inhibition Ovulation , Patch , Ethinylestradiol Gestodene</brief_title>
	<detailed_description>Study suspend due inconclusive toxicology finding regard use patch formulation clarify prior re-start study .</detailed_description>
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Gestodene</mesh_term>
	<mesh_term>Femovan</mesh_term>
	<criteria>Signed informed consent , BMI : 18 30 kg/mÂ² , Healthy female volunteer , Age 1835 year ( smoker old 30 year , inclusive ) , Ovulatory pretreatment cycle , least 3 month since delivery , Abortion lactation first screen examination , Willingness use nonhormonal method contraception entire study Contraindications use combine ( estrogen/gestodene ) contraceptive ( e.g . history venous/arterial thromboembolic disease Regular intake medication OCs Clinically relevant finding ( blood pressure , physical gynaecological examination , laboratory examination ) Anovulatory pretreatment cycle</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Female Contraception</keyword>
	<keyword>Ovulation Inhibition</keyword>
</DOC>